Johnson & Johnson (JNJ)
| Market Cap | 460.40B |
| Revenue (ttm) | 92.15B |
| Net Income (ttm) | 25.12B |
| Shares Out | 2.41B |
| EPS (ttm) | 10.35 |
| PE Ratio | 18.47 |
| Forward PE | 17.11 |
| Dividend | $5.20 (2.72%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 9,471,947 |
| Open | 191.48 |
| Previous Close | 190.85 |
| Day's Range | 189.30 - 193.57 |
| 52-Week Range | 140.68 - 194.40 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 197.75 (+3.44%) |
| Earnings Date | Oct 14, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $197.75, which is an increase of 3.44% from the latest price.
News
J&J faces first UK lawsuits alleging its baby powder caused cancer
Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.
These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings
Johnson & Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.
Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.
Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business
Johnson & Johnson on Tuesday raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations, and announced plans to spin off its orthopedics business into a sta...
'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations
Johnson & Johnson CFO and Executive Vice President Joe Wolk addresses the decision to spin off its orthopedics business, explains its innovations and more on ‘The Claman Countdown.'
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wol...
Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides
While big banks as a group posted strong earnings, Diane King Hall notes Citigroup (C) as a standout. She talks about how stronger IPO and dealmaking markets added muscle for the company.
Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again
Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 millio...
Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast
Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings and revealed plans to spin off its orthopedics business into a standalone comp...
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.
Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff
Johnson & Johnson's stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate its orthopedics business.
J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth
Johnson & Johnson chairman and CEO Joaquin Duato joins 'Squawk Box' to discuss the company's quarterly earnings results, adding warning labels to its multiple myeloma treatment Carvykti, the decision ...
J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains
Johnson & Johnson raised its full-year sales outlook as it posted gains in both its prescription-drug and medical-device businesses in the latest quarter.
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend.
J&J to spin off orthopedics business, raises full-year forecast
Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20...
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational ...
Johnson & Johnson said Tuesday it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes
The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fueled ...
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financ...
Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its or...
US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy
The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal...
Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company establi...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.